**South San Francisco, CA – May 16, 2022** – PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoantigen-specific T cell receptor (neoTCR) T cell therapies for the eradication of solid tumors, today announced that new data on PACT^NV™, the company’s non-viral precision gene editing technology, were highlighted in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting. Presented findings demonstrated the potential of the PACT^NV technology to enhance the functionality and applicability of T cell-based therapeutics, as well as other cellular therapies, through targeted gene editing. Specifically, researchers showed the ability of the versatile platform to knock-out, knock-down, knock-in and precisely regulate target genes in a single step to achieve desired activity for its neoTCR T cells. The ASGCT conference is being held May 16-19, 2022, in Washington, D.C.

The poster presentation reported research findings by PACT scientists demonstrating the ability to utilize the company’s PACT^NV technology to generate TCR T cells in a single step. In creating these novel patient-specific neoTCR T cells, PACT highlighted the following capabilities of its gene editing platform:

•	Insertion and expression of neoTCRs within T cells. 

•	Simultaneous elimination of the expression of the endogenous TCRs within same T cells.

•	Knock-out of the transforming growth factor beta (TGF-β) receptor type 2 (TGFBR2) gene, generating a T cell that can both recognize a patient-specific tumor and is resistant to the immunosuppressive signaling by TGF-β.

•	shRNA driven knock-down of multiple additional genes without any associated double-stranded break, generating enhanced T cells that can both recognize a patient-specific tumor and, depending on the targeted transcript, possess resistance to immunosuppression, increased persistence, and/or improved functional avidity.

•	Development of T cell activation-induced promoters for conditional expression of payloads.  

“Taken together, the powerful gene editing capabilities possessed by our PACT^NV platform offer the potential to expand the applicability of T cell therapeutics, while extending the potential use of the technology to other cellular therapies,” said Stefanie Mandl, Ph.D., senior vice president, head of research at PACT Pharma. “We are particularly excited about the versatility to add, eliminate and/or precisely modulate multiple genes within our neoTCR T cells to create novel, personalized therapeutic candidates with the potential to address a range of solid tumors. We look forward to continuing our research and development efforts in support of our PACT^NV technology, while continuing our ongoing Phase 1 clinical trial of non-viral PACT^NV™ gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors.”
  
PACT is currently conducting a Phase 1 clinical trial evaluating the safety, tolerability and feasibility of adoptive cell therapy with its non-viral PACT^NV gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors. This trial, in combination with extensive preclinical studies, has provided the company with unique data sets and insights derived from the core technologies that comprise its personalized adoptive T cell therapy platform for the treatment of solid tumors. 

A copy of the poster presented at the ASGCT conference is available on the “Abstracts & Publications” page of the PACT Pharma website [here](https://storage.googleapis.com/pact-assets/ASGCT-2022-Lu/ASGCT-2022-Lu.pdf).

**About PACT Pharma, Inc.**
PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial.

Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, non-viral precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.

For more information, please visit www.pactpharma.com.

**Contacts:**

PACT Pharma
Atulya Agarwal 
atulya@pactpharma.com

Vida Strategic Partners (on behalf of PACT Pharma)
Tim Brons (Media)
415-675-7402
tbrons@vidasp.com

PACT Pharma Highlights Capabilities and Versatility of Novel Non-Viral Gene Editing Technology in Presentation at American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

Press Releases

**South San Francisco, CA – April 11, 2022** – PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoantigen-specific T cell receptor (neoTCR) T cell therapies for the eradication of solid tumors, today announced that new data highlighting several aspects of its first-of-its-kind personalized neoantigen platform for adoptive cell therapies were presented in five separate poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022. The breadth of presented data reflects the expansive collection of pioneering insights into patient-specific TCR repertoires against solid tumors that the company has been able to accumulate through analysis of research samples, as well as patient samples from its ongoing first-in-human Phase 1 trial. The AACR conference is being held April 8-13, 2022, in New Orleans, Louisiana. 

“The scope of presented findings at AACR highlights the significant progress that we have made across all aspects of our unique neoTCR T cell therapy platform, spanning identification and verification of patient-specific tumor driving mutations, gene editing, cell manufacturing, machine learning and bioinformatics,” said Stefanie Mandl, Ph.D., senior vice president, head of research at PACT Pharma. “This continued progress speaks to the dynamic research and development approach that we are undertaking at PACT, as we aggressively advance our clinical-stage assets in human studies while using the evolving data set and learnings from our Phase 1 trial to continue to enhance various aspects of our technology platforms. This constellation of activities is focused on the single goal of bringing much needed, first-of-its kind neoTCR T cell therapies to patients battling solid tumors.”
  
PACT is currently conducting a Phase 1 clinical trial evaluating the safety, tolerability and feasibility of adoptive cell therapy with its non-viral PACT^NV™ gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors. This trial, in combination with extensive preclinical studies, has provided the company with unique data sets and insights derived from the core technologies that comprise its personalized adoptive T cell therapy platform for the treatment of solid tumors. 

Key presented findings at AACR included:

*imPACT Isolation Technology® Platform for TCR Discovery and Validation: Identifies TCRs to  Patient-Specific Tumor Driver Mutations*

By applying its imPACT Isolation Technology® platform to peripheral blood samples of more than 170 patients with solid tumors, PACT generated key findings on the relative distribution of patient-private mutations versus mutations in known cancer driver genes. Data demonstrated that tumor-specific T cells preferentially recognize patient-private mutations. However, TCRs that target known cancer driver mutations were shown to constitute > 5% of the functionally characterized TCRs, highlighting a high-value opportunity for “off-the-shelf” TCR therapies. Based on these findings, PACT is expanding its platform to develop such “off-the-shelf” treatments, and anticipates filing an investigational new drug (IND) application in the second half of 2022.

*Proprietary Machine Learning and Bioinformatics Optimize Personalized Treatment Strategies*

In two separate AACR posters, PACT highlighted its continued work building and utilizing its PACTImmune™ Database with extensive pre-, on- and post-treatment data from its ongoing Phase 1 trial. Analysis of this maturing data set with proprietary machine learning and bioinformatics produced new insights into patient-specific tumor immunogenicity in solid cancers, providing opportunities to optimize personalized neoTCR T cell treatment. The company’s application of its proprietary PACT-ESCAPE™ technology provided key learnings regarding neoepitope presentation escape mechanisms, which is a critical aspect of personalized TCR-based immunotherapy. 

*PACT^NV™: Efficiently Enabling Single-Step Precision Gene Editing*

In two separate poster presentations, PACT reported continued progress with PACT^NV, the company’s non-viral precision gene editing approach for generating clinical-grade TCR T cells for adoptive cell therapy. Importantly, the company has demonstrated the ability to execute precise, time-efficient, single-step gene editing to simultaneously knock-out TCR genes and insert neoantigen-specific TCRs isolated from a patient’s own blood. Furthermore, the company described its success incorporating additional complex modifications, which are intended to address challenges presented by the immunosuppressive nature of some tumor microenvironments, into the single-step gene editing process.

Copies of the posters presented at the AACR conference are available on the “Events” page of the PACT Pharma website at: https://www.pactpharma.com/news/?filter=events.

**About PACT Pharma, Inc.**
PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial.

Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, non-viral precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.

For more information, please visit www.pactpharma.com.

**Contacts**:

PACT Pharma
Atulya Agarwal
atulya@pactpharma.com

Vida Strategic Partners (on behalf of PACT Pharma)
Tim Brons (Media)
415-675-7402
tbrons@vidasp.com

PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022

**South San Francisco, CA – November 15, 2021** – PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that new data related to its PACTImmune™ Database were presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting. The results were featured in a poster presentation (#820) entitled, “Machine learning significantly improves neoantigen-HLA predictions utilizing > 26,000 data points from the PACTImmune Database,” at the SITC conference, which was held November 10-14, 2021. 

The presented results reported findings from a study in which PACT applied machine learning to more than 26,000 manufactured polypeptides consisting of the initially predicted neoE peptide together with Beta-2-Microglobulin and the HLA heavy chain for 62 different HLA alleles. Data demonstrated that PACT’s approach significantly improved neoE-HLA predictions, resulting in a 22% improvement in success rates on prospective data as compared to the widely used netMHCpan4.1 predictions. Additionally, the presentation outlined key elements of PACT’s strategy for continued enhancements to its approach to further improve its predictive power. 

“The PACTImmune Database enables us to tune and continue to learn from our platform and its growing data assets. Based on retrospective analysis we know that higher predicted neoE-HLA success corelates with more TCRs captured per patient. Ultimately, these improved predictions should give us more actionable neoTCR options for patients in our clinical trial,” said Eric Stawiski, Vice President of Bioinformatics at PACT and presenter of the SITC poster.

The abstract related to this presentation is available on the SITC website and can be accessed at: [https://jitc.bmj.com/content/9/Suppl_2/A858](https://jitc.bmj.com/content/9/Suppl_2/A858).

**About PACTImmune™ Database**
PACT has developed a proprietary approach to validate predicted neoepitopes (neoEs) and their cognate T cell receptors (neoTCRs) by capturing neoepitope-specific T cells from peripheral blood. This neoTCR discovery and validation process is being applied in a clinical trial (NCT03970382) evaluating personalized neoTCR-T cell therapy to treat patients across eight solid tumor types. Extensive pre-, on- and post-treatment data related to this trial has been accumulated in the PACTImmune Database (PIDB) which represents a growing data asset for patient-specific tumor immunogenicity in solid tumors.

**About PACT Pharma, Inc.**
PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial.

Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, cutting edge (non-viral) precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.

For more information, please visit [www.pactpharma.com](https://www.pactpharma.com).

Contacts:

**PACT Pharma**
Atulya Agarwal 
atulya@pactpharma.com

**Vida Strategic Partners (on behalf of PACT Pharma)**
Tim Brons (Media)
415-675-7402
tbrons@vidasp.com


PACT Reports New Data Highlighting Predictive Power of Machine Learning Approach Leveraging PACTImmune™ Database at Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

PACT is a company pushing the frontiers of science, technology and medicine. We are creating T cell therapies to alter the course of cancer and meaningfully impact the lives of patients who urgently need breakthrough therapies. We are building a team of driven, talented and passionate individuals committed to bringing these novel personalized therapies to people living with cancer.

Join Us

PACT is a clinical stage immuno-oncology company dedicated to engineering T cell therapies by seeking to harness the inherent biology and curative potential of each patient's immune system to treat their cancer and advance the field of immune-driven medicines.

Who We Are

“I joined PACT to work with our impressive management team and innovative technologies to improve cancer therapies. It is the people that make this company exceptional and the mission to cure cancer that motivates me.”

thumbnail_Rebecca.jpg

Rebecca.jpg

Director

"I joined PACT because of the science and the people!  PACT is a special place where people work hard because they are passionate about the science, committed to patients, value teamwork and push the boundaries to never accept the status quo. For those who thrive in a fast paced and innovative environment, PACT provides a rewarding opportunity to tackle challenging projects in a collaborative way."

thumbnail_Susan.png

Susan.png

Vice President

“When I first interviewed at PACT, I remember being impressed by the collaborative and open nature of research within the company. It left quite the impression with me and ultimately guided me towards choosing a career at PACT. Since joining, I am continually grateful for the level of openness and collaboration between teams and departments that is crucial for pioneering scientific work."


Accelerating CurativeT Cell Therapiesfor Cancer

Tailored for Each and Every Person

PACT Pharma Highlights Capabilities and Versatility of Novel Non-Viral Gene Editing Technology in Presentation at...

Who We Are

Mission & Vision

Our
Platform

Our
Programs

PACT Voices

Director

Technical Operations

Vice President

Program Management

Scientist

Tumor Immunology

Join Us

Accelerating CurativeT Cell Therapiesfor Cancer

Tailored for Each and Every Person

PACT Pharma Highlights Capabilities and Versatility of Novel Non-Viral Gene Editing Technology in Presentation at...

Who We Are

Mission & Vision

OurPlatform

OurPrograms

PACT Voices

Director

Technical Operations

Vice President

Program Management

Scientist

Tumor Immunology

Join Us

Our
Platform

Our
Programs